Pfizer beat third-quarter expectations and raised its 2021 forecast again even as sales of its top product, the COVID-19 vaccine Comirnaty, slipped in the U.S. Soaring international sales of the preventive shots helped pushed total Comirnaty revenue close to $13 billion in the quarter, and the drugmaker said Tuesday that it now expects to book about $36 billion in sales from the vaccine this year
Related posts
-
Finance director’s retirement is latest administrative turnover at Arlington Heights village hall
Arlington Heights’ longtime Finance Director Tom Kuehne is set to retire in February amid a recent... -
America reaches Election Day and a stark choice between Trump and Harris
A presidential campaign marked by upheaval and rancor approached its finale on Election Day as Americans... -
Bears coaches feel heat, but don’t forget about bad drafts of past
The Bears season is losing steam quickly, but Sunday’s loss in Arizona was another reminder that...